Researchers have shown that people 60 years or older with weakened immunity do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function.
Quelle: ScienceDaily | Immunsystem
Titelbild/Grafik: ScienceDaily News
Kommentare und Fragen
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- Ultrasound-directed microbubbles could boost immune response against tumors
- Scientists develop tiny anticancer weapon
- 'Perfect storm' of mutations drives infection-triggered autoimmune disease
- Three drug cocktail shows potential to boost CAR-T cancer therapy
- A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior
- Immunotherapy against cancer: How therapeutic antibodies do their job
- T cells' capability to fully prevent acute viral infections opens new avenues for vaccine development
- Researchers shed light on how to predict which skin cancer patients are most likely to respond to immunotherapy
- Scientists unveil surprising human vs mouse differences in a major cancer immunotherapy target
- Targeting tristetraprolin in basophils: A breakthrough in allergic inflammation treatment
